Background: Primary bone lymphoma is a rare disease, representing less than 5% of all extra-nodal non-Hodgkin lymphomas. Materials and Methods: We retrospectively searched the database of the lymphoma unit, Hematology/Lymphoma Department, Athens General Hospital ‘Evangelismos' for primary bone lymphoma patients. Demographic and clinicopathologic data were collected and overall survival was analyzed. A log-rank test was used in a univariate analysis to identify factors affecting overall survival. Results: We identified 24 and analyzed data from 22 patients. 12 were male (54.5%) and 10 female (45.4%) and their median age was 55 years (range: 19-83). Most patients had localized disease at the time of diagnosis (n = 19, 86.3%), the most common site was the spine (n = 11, 50%) and the most common histology was diffuse large B-cell lymphoma. 21 patients received chemotherapy as initial therapy and 16 received combined chemoradiation. 81.8% of the patients (n = 18) achieved complete remission. 5-year survival rate was 86.3% and overall survival was found to be affected by the patients' initial response to treatment. Conclusions: Primary bone lymphoma is usually associated with a good prognosis. Prospective studies are needed in order to clarify the effect of immunochemotherapy in overall survival.

Keywords:
Primary bone lymphoma, DLBCL, Chemotherapy, Rituximab
1.
Parker F, Jackson H: Primary reticulum cell sarcoma of bone. Surg Gynecol Obstet 1939;68:45-53.
2.
Fidias P, Spiro I, Sobczak ML, Nielsen GP, Ruffolo EF, Mankin H, Suit HD, Harmon DC: Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys 1999;45:1213-1218.
3.
Beal K, Allen L, Yahalom J: Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006;106:2652-2656.
4.
Limb D, Dreghorn C, Murphy JK, Mannion R: Primary lymphoma of bone. Int Orthop 1994;18:180-183.
5.
Dubey P, Ha CS, Besa PC, Fuller L, Cabanillas F, Murray J, Hess MA, Cox JD: Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys 1997;37:1087-1093.
6.
Freeman C, Berg JW, Cutler SJ: Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252.
7.
Jawad MU, Schneiderbauer MM, Min ES, Cheung MC, Koniaris LG, Scully SP: Primary Lymphoma of Bone in Adult Patients. Cancer 2010;116:871-879.
8.
Swerdlow SH, Steven H: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4th). Lyon, France: IARC Press; 2008.
9.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
10.
Mikhaeel NG: Primary Bone Lymphoma. Clin Oncol 2012;24:366-370.
11.
Wang J, Kim D, Goldberg M: Anaplastic Large Cell Ki-1 Lymphoma: Primary Bone Presentation in an Elderly Man. Acta Haematol 1996;96:45-49.
12.
Tanimura A, Adachi Y, Tanda M, Yuasa H, Ishii Y, Katou Y: Primary Peripheral B Cell Lymphoma, Burkitt-Like, of the Cranial Vault. Acta Haematol 2005;113:258-261.
13.
Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim SW, Tanimoto K, Makimoto A, Kagami Y, Terauchi T, Matsuno Y, Tobinai K: Primary Bone Lymphoma: A New and Detailed Characterization of 28 Patients in a Single-Institution Study. Jpn J Clin Oncol 2007;37:216-223.
14.
Ueda T, Aozasa K, Ohsawa M, Yoshikawa H, Uchida A, Ono K, Matsumoto K: Malignant lymphomas of bone in Japan. Cancer 1989;64:2387-2392.
15.
Heyning FH, Hogendoorn PC, Kramer MH, Hermans J, Kluin-Nelemans JC, Noordijk EM, Kluin PM: Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia 1999;13:2094-2098.
16.
Zinzani PL, Carrillo G, Ascani S, Barbieri E, Tani M, Paulli M, Stefoni V, Sabattini E, Alinari L, Binazzi R, Tura S, Baccarani M, Pileri SA: Primary Bone Lymphoma: experience with 52 patients. Haematologica 2003;88:280-285.
17.
Ramadan KM, Shenkier T, Sehn LH, Gascoyne RD, Connors JM: A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann of Oncol 2007;18:129-135.
18.
Dosoretz DE, Murphy GF, Raymond AK, Doppke KP, Schiller AL, Wang CC, Suit HD: Radiation therapy for primary lymphoma of bone. Cancer 1983;51:44-46.
19.
Stein ME, Kuten A, Gez E, Rosenblatt KE, Drumea K, Ben-Shachar M, Zidan J, Haim N, Epelbaum R: Primary lymphoma of bone - a retrospective study. Oncology 2003;64:322-327.
20.
Lewis VO, Primus G, Anastasi J, Doherty D, Montag AG, Peabody TD, Simon MA: Oncologic outcomes of primary lymphoma of bone in adults. Clin Orthop Relat Res 2003;415:90-97.
21.
de Leval L, Braaten KM, Ancukiewicz M, Kiggundu E, Delaney T, Mankin HJ, Harris NL: Diffuse large B-cell lymphoma of bone. An analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol 2003;27:1269-1277.
22.
Barbieri E, Cammelli S, Mauro F, Perini F, Cazzola A, Neri S, Bunkheila F, Ferrari S, Brandoli V, Zinzani P, Mercuri M, Bacci G: Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for stage I and stage II. Int J Radiat Oncol Biol Phys 2004;59:760-764.
23.
Horsman JM, Thomas J, Hough R, Hancock BW: Primary bone lymphoma: a retrospective analysis. Int J Oncol 2006;28:1571-1575.
24.
Alencar A, Pitcher D, Byrne G, Lossos IS: Primary bone lymphoma - the University of Miami experience. Leuk Lymphoma 2010;51:39-49.
25.
Pellegrini C, Gandolfi L, Quirini F, Ruggieri P, Stefoni V, Derenzini E, Broccoli A, Argnani L, Pileri S, Mercuri M, Baccarani M, Zinzani PL: Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients. Clin Lymphoma Myeloma Leuk 2011;11:321-325.
26.
Nasiri MR, Varshoee F, Mohtashami S, Raziee HR, Aledavood A, Ghafarzadeh K, Memar B, Vojdani S, Sarvizadeh M: Primary bone lymphoma: a clinicopathological retrospective study of 28 patients in a single institution. J Res Med Sci 2011;16:814-820.
27.
Cai L, Stauder MC, Zhang YJ, Poortmans P, Li YX, Constantinou N, Thariat J, Kadish SP, Nguyen TD, Kirova YM, Ghadjar P, Weber DC, Bertran VT, Ozsahin M, Mirimanoff RO: Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study. Int J Radiat Oncol Biol Phys 2012;83:284-291.
28.
Kim SY, Shin DY, Lee SS, Suh C, Kwak JY, Kim HG, Lee JH, Lee SI, Lee YR, Kang SH, Mun SK, Lee MJ, Lee HR, Yang SH, Kang HJ: Clinical characteristics and outcomes of primary bone lymphoma in Korea. Korean J Hematol 2012;47:213-218.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.